Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer.

Cancer medicine - 1 Jun 2018

Elsayegh Nisreen, Webster Rachel D, Gutierrez Barrera Angelica M, Lin Heather, Kuerer Henry M, Litton Jennifer K, Bedrosian Isabelle, Arun Banu K

Abstract excerpt

Although multigene panel testing is increasingly common in patients with cancer, the relationship between its use among breast cancer patients with non-BRCA mutations or variants of uncertain significance (VUS) and disease management decisions has not been well described. This study evaluated the rate and predictive factors of CPM patients who underwent multigene panel testing. Three hundred and fourteen patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Breast Neoplasms

Share to Genetic Testing

Share to Incidence

Share to Prophylactic Mastectomy

Share to Proportional Hazards Models

Source

Open in PubMed Open full text

Identifiers

PMID: 29733510
DOI: 10.1002/cam4.1519
PMCID: PMC6010764

Genes

CPM

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer.PMID 29733510Read ↗

Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing.Semantic proximity Read ↗

Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients.Semantic proximity Read ↗

Genetic testing and surgical treatment after breast cancer diagnosis: Results from a national online cohort.Semantic proximity Read ↗

Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.Semantic proximity Read ↗

Association of Moderate-Risk Breast Cancer Genes with Contralateral Prophylactic Mastectomy and Bilateral Disease.Semantic proximity Read ↗

ASO Author Reflections: Performance of Contralateral Risk-Reducing Mastectomy in Multigene Panel-Tested Patients is High in All Types of Germline Mutation Carriers.Semantic proximity Read ↗

Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result.Semantic proximity Read ↗

Negative Genetic Testing Does Not Deter Contralateral Prophylactic Mastectomy in Younger Patients with Greater Family Histories of Breast Cancer.Semantic proximity Read ↗

Differences Among a Modern Cohort of BRCA Mutation Carriers Choosing Bilateral Prophylactic Mastectomies Compared to Breast Surveillance.Semantic proximity Read ↗

Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes.Semantic proximity Read ↗

Multi gene panel testing for hereditary breast cancer - is it ready to be used?Semantic proximity Read ↗

Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.